(PharmaNewsWire.Com, January 22, 2018 ) The Global Uterine Cancer Therapeutics Market is expected to reach $22,686.3 million by 2021 from $17,399.3 million in 2016, growing at a CAGR of 5.45% during the forecast period 2016-2021. Uterine cancer is one of most commonly prevailing malignant tumours that starts in the cells of the uterus and spreads to other parts of the body. Uterine cancer is mainly of two types such as uterine sarcoma and endometrial carcinoma. Till now more numbers of therapies have been evolved to manage uterine cancer types include surgery, chemotherapy, radiation therapy, immunotherapy, and hormone therapy.
Increasing healthcare expenditure, rising focus of government to provide effective healthcare solutions, growing advancements in the cancer screening & treatment methods, and increasing number of newly diagnosed uterine cancer cases are driving the growth of the global Uterine Cancer Therapeutics market. In addition, increasing advancements in molecular diagnostics industry to support target specific therapies and rising awareness among patients is further stimulating the global Uterine Cancer Therapeutics market. However, dearth of superior healthcare infrastructure in certain developing countries, lack of efficient communication between women & health care providers, high cost of the uterine cancer treatment solutions, improper reimbursement policies, and stringent regulatory framework are restraining the growth of global Uterine Cancer Therapeutics market.
The Global market for Uterine Cancer Therapeutics is broadly categorized into type and therapy. On the basis of type global Uterine Cancer Therapeutics market is segmented into Uterine Sarcoma and Endometrial Carcinoma (Adenocarcinoma, Carcinosarcoma, Squamous cell carcinoma, & Others). Of these, Endometrial Carcinoma is expected to hold the major market share in the global Uterine Cancer Therapeutics market. Based on therapy the market is segmented into Surgery, Chemotherapy, Radiation Therapy, Immunotherapy, and Hormone Therapy.
On the basis of geography, the global market is analysed under various regions namely North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa. North America is the dominating market for Uterine Cancer Therapeutics accounting for a share of approximately 34% followed by Europe in 2016. Asia-Pacific is estimated to be the fastest growing region with a CAGR of 6.51% during the forecast period of 2016-2021.
Key market players in the global Uterine Cancer Therapeutics market such as Abbott Laboratories (U.S.), Ariad Pharmaceuticals, Inc. (U.S.), Becton, Dickinson and Company (U.S.), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline Plc (U.K.), Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Sanofi (France), Siemens Healthcare GmbH (Germany), and Takeda Pharmaceutical Company Ltd. (Japan).
About Us: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialties with competitive pricing options.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
